• Similar articles
    BreastMalaysiantribune
    Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
    Jan 10. Health: SHANGHAI, China, Jan. 09, 2024 — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery…
    SHANGHAI, China, Jan. 09, 2024 — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery…
    Malaysiantribune
    Shanghai Junshi Biosciences Co
    30, 2023 — Shanghai (archive) Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180),…Malaysiantribune
    Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates
    Aug 31 2023. Finance: 2023 — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-…
    2023 — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-…
    Malaysiantribune
    Similar
    Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
    Apr 9 2022. Health: April 09, 2022 — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced the results of the SHANGHAI, China, and REDWOOD CITY,…
    April 09, 2022 — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced the results of the SHANGHAI, China, and REDWOOD CITY,…
    Malaysiantribune
    Similar
    Junshi Biosciences Announces First Patient Dosed in China (archive) in Phase III Clinical Trial of VV116… PixabayMalaysiantribune
    Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial of VV116 in Treatment of Moderate to Severe COVID-19
    Mar 16 2022. Health: 2022 — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-…
    2022 — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-…
    Malaysiantribune
    Similar

    About NewsOwner

    We are tracking and analysing news

    Add website

    Send us news sources you want us to cover

    Advertise

    Advertising and sponsored content

    Contact us

    Send us your comments or questions here

    Copyrights © 2016 - Scanmine Inc. / NewsOwner.com. This publication is automatically generated based on content updated from thousands of sources. All article content are © copyright of their respective owners. Third party content is collected from open sources only and selected, filtered and used by the creator of this publication similar to how third party content is posted by users in social media platforms or generated from search engines and in line with the U.S. "Fair Use Act" and similar laws in other countries allowing limited use of copyrighted material.